Aptose Biosciences: Hanmi Acquisition Delayed, Deepening Cash Crisis
APTOF has more than doubled off its 52-week low of $0.636 on light trading volume (0.1× avg).
Summary
Aptose Biosciences announced a further delay in the closing of its acquisition by Hanmi Pharmaceutical, citing ongoing Korean regulatory approvals. This acquisition, approved by shareholders and court in late March, was previously highlighted as a critical 'positive resolution' for the financially distressed company. The delay is particularly concerning given Aptose's recent disclosure in mid-May that it lacks sufficient cash to fund ongoing operations. This postponement of the expected cash infusion significantly exacerbates the company's liquidity crisis and raises immediate questions about its operational viability.
At the time of this announcement, APTOF was trading at $1.57 on OTC in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $0.64 to $2.50. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.